Nurexone Biologic Inc. Reveals Q2 2025 Financial Results
Nurexone Biologic reported its second-quarter 2025 results and advanced a series of steps toward first-in-human testing of ExoPTEN, its...
Jon Napitupulu
FDA Approves Idorsia’s Tryvio for Systemic Hypertension
Idorsia is sharpening the commercial and scientific positioning of Tryvio (aprocitentan), releasing an on-demand webcast that frames the first-in-class...
MannKind to Acquire scPharma, Accelerating Growth
MannKind Corporation’s acquisition of scPharmaceuticals for up to $360 million, including milestone-based contingent value rights (CVRs), marks a decisive...
Proxygen & EPFL Team Up for AI Glue Discovery
Proxygen, a leader in molecular glue degrader discovery and development, has partnered with the Swiss Federal Institute of Technology...
Pharmather Announces FDA Approval of Ketarx™ (Ketamine)
PharmaTher Holdings Ltd. is aggressively pursuing a dual-pronged strategy centered around its recently FDA-approved ketamine product, KETARx™. The company...
CDT Equity Validates AI-Driven Strategy with New Biological Target
CDT Equity Inc. has identified a new therapeutic indication for its lead program, AZD1656, based on promising pre-clinical data...
Odyssey Health to Advance Life-Saving Choking Rescue Device
Odyssey Health, a technology and asset acquisition company, is advancing the development of its patented Save a Life (SAL)...
Zenas BioPharma to Present at Healthcare Conferences
Zenas Biopharma, a clinical-stage biotech focused on autoimmune diseases, has announced its participation in three major investor conferences in...
Rakovina CSO to Present at Tuscany Retreat on Cancer Research
Rakovina Therapeutics’ Chief Scientific Officer, Dr. Mads Daugaard, presented at the 13th Tuscany Retreat on Cancer Research and Apoptosis,...
PathAI Broadens AI-Powered Diagnostics for Ventana Slide Scanners
PathAI expands FDA clearance for its AI-powered digital pathology image management system, AISight® DX, to include Roche’s Ventana DP...